Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471111 | 0.90 | HRH3 (0.76) | HRH3KCNH2ADRA1A | |
| SCHEMBL4474003 | 0.89 | HRH3 (0.76) | HRH3KCNH2ADRA1A | |
| SCHEMBL4485207 | 0.88 | HRH3 (0.69) | HRH3KCNH2ADRA1A | |
| Hydrochloric Acid SCHEMBL4469898 | 0.88 | HRH3 (0.68) | HRH3KCNH2ADRA1A | |
| SCHEMBL4466101 | 0.87 | HRH3 (0.98) | HRH3KCNH2ADRA1A | |
| SCHEMBL4464353 | 0.86 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4468136 | 0.83 | HRH3 (0.76) | HRH3KCNH2ADRA1AHRH1HRH4 | |
| SCHEMBL4462326 | 0.83 | HRH3 (0.76) | HRH3KCNH2ADRA1AHRH1HRH4 | |
| SCHEMBL23921278 | 0.82 | MAPT (0.59) | HRH3KCNH2 | |
| SCHEMBL4468005 | 0.82 | HRH3 (0.77) | HRH3KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | claimed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | claimed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.